Introduction: Developing new vaccines to combat emerging infectious diseases has gained more significance after the COVID-19 pandemic. Vaccination is the most cost-effective method for preventing infectious diseases, and subunit antigens are a safer alternative to traditional live, attenuated, and inactivated vaccines.
Areas Covered: Challenges in delivering subunit antigens and the status of different vaccine adjuvants. Recent research developments involving emulsion and liposomal adjuvants and their compositions and properties affecting their adjuvancy.
Expert Opinion: Lipid-based adjuvants, e.g. emulsions and liposomes, represent a paradigm shift in vaccine technology by enabling robust humoral and cellular immune responses with lower antigen doses, a property that is particularly critical during pandemics or in resource-limited settings. These adjuvants can optimize vaccine administration strategies by potentially reducing the frequency of booster doses, thereby improving patient compliance and lowering healthcare costs. While emulsions excel in dose-sparing and broadening immune responses, liposomes offer customization and precision in antigen delivery. However, the broader clinical application of these technologies is not without challenges. Stability issues, e.g. the susceptibility of emulsion-based adjuvants to freezing and their reliance on cold-chain logistics, pose significant barriers to their use in remote/underserved regions. Future developments will likely focus on improving manufacturing scalability and cost-effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425247.2025.2474088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Immune Responses through Modulation of Innate Cell Microenvironments in Lymph Nodes with Virus-Mimetic Vaccines.
Angew Chem Int Ed Engl
March 2025
Fudan University, 131, Dongan Road, Shanghai, CHINA.
Nanovaccines hold significant promise for the prevention and treatment of infectious diseases. However, the efficacy of many nanovaccines is often limited by inadequate stimulation of both innate and adaptive immune responses. Herein, we explore a rational vaccine strategy aimed at modulating innate cell microenvironments within lymph nodes (LNs) to enhance the generation of effective immune responses.
View Article and Find Full Text PDFAntenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and Treatment.
Open Forum Infect Dis
December 2024
Institute for Infection and Immunity, St George's, University of London, London, United Kingdom.
Background: Hepatitis B virus (HBV) infection is a significant cause of morbidity and mortality globally. The World Health Organization estimates that just 10.5% of individuals living with HBV globally are aware of their status.
View Article and Find Full Text PDFFormulation and development of ACUPA-targeting PEGylated nanoliposomes for treatment of prostate cancer.
Tissue Cell
March 2025
Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospitals, Saveetha University, Chennai, India; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
A promising strategy for improving the effectiveness, specificity and safety of cancer treatment is targeted medication delivery. Prostate-specific membrane antigen (PSMA) is an effective biomarker for tracking and treating prostate cancer. In this study, we developed a PSMA-targeted drug delivery system by modifying PEGylated liposomal doxorubicin (PLD) with 2-(3-((S)-5-amino-1-carboxypentyl) ureido) pentanedioic acid (ACUPA), a small-molecule PSMA inhibitor, to enhance tumor targeting and therapeutic outcomes.
View Article and Find Full Text PDFBLIMP-1-dependent differentiation of T follicular helper cells into Foxp3 T regulatory type 1 cells.
Front Immunol
March 2025
Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
T-regulatory-type-1 (TR1) cells are a subset of interleukin-10-producing but Foxp3 Treg cells that arise in response to chronic antigenic stimulation. We have shown that systemic delivery of autoimmune disease-relevant peptide-major histocompatibility complex class II (pMHCII)-coated nanoparticles (pMHCII-NP) triggers the formation of large pools of disease-suppressing Foxp3 TR1 cells from cognate T-follicular helper (TFH) cell precursors. Here we show that, upon treatment withdrawal, these Foxp3 TR1 cells spontaneously differentiate into a novel immunoregulatory Foxp3 TR1 subset that inherits epigenetic and transcriptional hallmarks of their precursors, including clonotypic T-cell receptors, and is distinct from other Foxp3 Treg subsets.
View Article and Find Full Text PDFManganese-Driven Plasmid Nanofibers Formed for Cancer Gene Delivery and Metalloimmunotherapy.
J Am Chem Soc
March 2025
School of Chemical Engineering and Technology, State Key Laboratory of Synthetic Biology, Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin, P. R. China, 300350.
While nucleic-acid-based cancer vaccines hold therapeutic potential, their limited immunogenicity remains a challenge due in part to the low efficiency of cytoplasmic delivery caused by lysosomal entrapment. In this work, we found that plasmids encoding both an antigen and a STING agonist protein adjuvant can self-assemble into coordination nanofibers, triggered by manganese ions. We developed a strategy to construct a DNA vaccine, termed MnO-OVA-CDA-mem, formed by the coencapsulation of manganese dioxide (MnO), an antigen-expressing plasmid (encoding ovalbumin, OVA), and an adjuvant enzyme-expressing plasmid (encoding STING agonist, CDA) within dendritic cell (DC) membranes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!